A recent review examined the current evidence regarding risk factors, molecular characterization, and treatment options for myeloproliferative neoplasms.
Myeloproliferative neoplasms (MPNs) represent a heterogenous group of disorders of the hematopoietic stem cell, with a high risk of evolution into acute myeloid leukemia (AML). Prognosis is poor, with a medium overall survival ranging from 2.6 to 7 months. A recent review examined the current evidence regarding risk factors, molecular characterization, and treatment options.
The major causes of morbidity and mortality are usually thrombohemorrhagic events and less frequently infectious complications, and/or transformation to blast phase, often termed secondary AML or blast-phase MPN (MPN-BP). The term MPN-BP has been proposed by the International Working Group for Myelofibrosis Research and Treatment to reflect the occurrence of leukemic transformation in the classical BCR-ABL1—negative MPNs.
Currently, there is no standard of care for managing the blast phase of these diseases; no treatment has consistently led to prolonged survival and/or hematological remission apart from an allogeneic stem cell transplant, the authors wrote.
The frequency of leukemic evolution varies according to the subtype of MPN. It is highest in primary myelofibrosis (PMF), where it is estimated to be approximately 10% to 20% at 10 years, followed by polycythemia vera, with a risk of 2.3% at 10 years and 7.9% at 20 years. AML transformation in essential thrombocythemia is considered relatively rare.
Different factors are associated with leukemic evolution in MPN, but generally include advanced age, leukocytosis, exposure to myelosuppressive therapy, cytogenetic abnormalities, and increased number of mutations in genes associated with myeloid neoplasms.
Independent risk factors for leukemic transformation in PMF include peripheral blood (PB) blast greater than 3% and platelet count less than 100 x 109 L. Other proposed risk factors include increased serum interleukin 8, or C-reactive protein levels, age older than 65 years, and PB blast count greater than 1%.
Unfavorable karyotype and thrombocytopenia were also identified as being the most important risk factors for leukemic evolution in PMF.
Regarding biological risk factors, a complex/monosomal karyotype is one important risk factor, as a favorable karyotype is infrequent in MPN-BP. In addition, several recurrent gene mutations, including those involving epigenetic modifiers and spliceosome machinery, are involved in this phase of the disease. Using a candidate gene approach, 5 mutated genes including ASXL1, SRSF2, EZH2, IDH1, and IDH2, were associated with shorter overall survival and leukemia-free survival, defining a high-molecular risk category.
MPN-BP represents an area of urgent clinical need, the researchers said. Conventional antileukemic therapy has limited efficacy in patients with BCR-ABL1—negative MPNs in accelerated or blast phase of the disease. Currently, stem cell therapy is the best option, but it first requires intensive chemotherapy to reduce the disease burden to become eligible. In most patients, advanced age and significant comorbidities disqualifies them from a transplant.
Effectively targeted chemotherapeutic agents that are currently available include 2 hypomethylating agents: 5-azacytidine (azacytidine) and 5-aza-2' deoxycitidine (decitabine).
Among future therapies, the researchers called CPX-351 (Vyxeos), a liposome formulation of cytarabine and daunorubicin, promising. It is approved for treatment of therapy-related or secondary AML.
The researchers said participation of patients in clinical trials should be strongly encouraged.
Reference
Iurlo A, Cattaneo D, Gianelli U. Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options [published online April 13, 2019]. Int J Mol Sci. doi: 10.3390/ijms20081839.
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More